RGC Resources' 15min chart shows KDJ Death Cross, Bearish Marubozu.

Amarin's 15-minute chart has triggered a narrowing of Bollinger Bands, and a KDJ Death Cross occurred on August 5th, 2025, at 15:45. This indicates a decline in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with a potential for further price decrease.

Amarin Corporation (AMRN) reported its second-quarter (Q2) 2025 earnings, which exceeded expectations and sparked a 2.2% stock price increase on July 30. The company reported a loss of 3 cents per share, significantly narrower than the Zacks Consensus Estimate of a loss of 66 cents per share [1]. Adjusted earnings per share (EPS) were 4 cents, up from 1 cent in the year-ago quarter. Total revenues reached $72.7 million, an 8% increase year-over-year (YoY), driven by higher licensing and royalty revenues [1].

Vascepa, Amarin's sole marketed drug, generated $46.6 million in net product revenues, down 2% YoY. U.S. product revenues from Vascepa declined 17% due to rising generic competition, while European revenues surged 85%. Licensing and royalty revenues increased 31% to $26.1 million, driven by an upfront payment under a new European licensing agreement with Recordati [1].

Amarin's stock has rallied 54.3% so far this year compared to the industry's 1% rise. However, recent technical indicators suggest a potential downside. Amarin's 15-minute chart has triggered a narrowing of Bollinger Bands, indicating a decline in price fluctuation magnitude. Additionally, a KDJ Death Cross occurred on August 5, 2025, at 15:45, signaling a shift in momentum towards the downside [2].

Despite the positive earnings report, investors should remain cautious due to these technical signals. Amarin's partnership with Recordati and its restructuring efforts aim to boost growth and cash position, but the potential downside risk highlighted by the technical indicators should not be overlooked.

References:
[1] The Globe and Mail. "Amarin's Q2 Earnings in Detail." https://www.theglobeandmail.com/investing/markets/stocks/CRMD-Q/pressreleases/33784729/amarin-s-q2-earnings-revenues-trump-estimates-stock-rises/
[2] Zacks Investment Research. "Amarin Corporation PLC: Free Stock Analysis Report." https://www.zacks.com/stock/quote/AMRN